Coherus Oncology (CHRS) EBITDA (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of EBITDA data on file, last reported at -$36.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 20.43% year-over-year to -$36.2 million; the trailing twelve-month figure through Mar 2026 stood at -$171.8 million (up 3.07% YoY), and the FY2025 full-year result was -$181.1 million, up 9.28% from the prior year.
• EBITDA advanced to -$36.2 million in Q1 2026, from -$45.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$32.0 million in Q3 2023 to a low of -$80.9 million in Q1 2022.
• A 5-year average of -$51.6 million and a median of -$45.5 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 145.37% in 2022 and soared 60.22% in 2023, its largest moves.
• Tracing CHRS's EBITDA over 5 years: stood at -$51.5 million in 2022, then slumped by 33.81% to -$68.9 million in 2023, then soared by 34.14% to -$45.4 million in 2024, then slipped by 1.09% to -$45.9 million in 2025, then gained by 21.21% to -$36.2 million in 2026.
• Business Quant data shows CHRS's EBITDA at -$36.2 million in Q1 2026, -$45.9 million in Q4 2025, and -$44.3 million in Q3 2025.